
|
Report Date : |
18.01.2007 |
|
Name : |
S ZHAVERI PHARMAKEM
PRIVATE LIMITED (w. e. f.
06.06.2005) |
|
|
|
|
Formerly Known As : |
S ZHAVERI AND COMPANY |
|
|
|
|
Registered Office : |
109, Shiv Smruti Chambers,49,
Dr. Annie Besant Road, Worli, Mumbai - 400018, India |
|
|
|
|
Country : |
India |
|
|
|
|
Financial (as on) : |
-- |
|
|
|
|
Date of Incorporation : |
06.06.2005 |
|
|
|
|
Com. Reg. No.: |
U51397MH2005PTC153790 |
|
|
|
|
TAN No.: (Tax Deduction & Collection
Account No.) |
MUMS48413B |
|
|
|
|
Legal Form : |
Private Limited
Liability Company |
|
|
|
|
Line of Business : |
The concern act as
indenting house engaged in marketing of pharmaceutical raw materials from foreign
manufacturers to multinational/ Indian Pharma/ Chemical factories and is also
engaged in contract research. |
|
MIRA’s Rating : |
Ba |
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered
normal. Capable to meet normal commitments. |
Satisfactory |
|
Maximum Credit Limit : |
-- |
|
|
|
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Usually correct |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is a well
established concern in its field. Partners are reported as experienced,
respectable and having satisfactory means of their own. Their trade relations
are fair. Payments are usually correct and as per commitments. The concern can be
considered normal for business dealings at usual trade terms and conditions. Management assured
to provide more details soon. |
|
Registered Office : |
109, Shiv Smriti
Chambers, 49, Dr. A.B.Road, Worli, Mumbai 400 018, India |
|
Tel. No.: |
91-22-66607756 |
|
Fax No.: |
91-22-66607758 |
|
E-Mail : |
|
|
Website : |
|
|
Area : |
375 Sq.ft. |
|
Location : |
Owned |
|
|
|
|
Head Office : |
E-7, Kasturi
Complex, Anjur Road, Rahanat Village, Bhiwandi – 421 302,
District Thane, Maharashtra, India |
|
E-Mail : |
|
|
Website : |
|
|
|
|
|
Factory: |
28/16, TTC
Industrial Area, MIDC Turbhe, Navi Mumbai – 400705 |
|
Tel. No.: |
91-22-67912851 / 67912852 |
|
Fax No.: |
91-22-67912853 |
|
Location
: |
Leased |
|
|
|
|
Warehouse: |
32, Kewal
Industrial Estate, S.B.Marg, Lower Parel, Mumbai 400 018, India |
|
Area
: |
400 Sq.ft. |
|
Location
: |
Rented |
|
|
|
|
Branches : |
236, Kewal
Industrial Estate, S.B.Marg, Lower Parel, Mumbai 400 018, India |
|
Area
: |
1000 Sq.ft. |
|
Location
: |
Rented |
|
|
|
|
Administration Office: |
45, Tardeo Air
Condition Market, Mumbai 400 018, India |
|
Name : |
Mr. Vinodchandra B.
Seth |
|
Designation : |
Director |
|
Qualification : |
B.Sc Chemistry |
|
|
|
|
Name : |
Mrs. Nalini V. Seth |
|
Designation : |
Director |
|
|
|
|
Name : |
Mrs. Uma Rajan
Javeri |
|
Designation : |
Director |
|
Address: |
1002, Jayant
Towers, Tardeo Road, Tardeo, Mumbai - 400034 |
|
Date of Birth/Age : |
49 years |
|
Qualification : |
B.Com |
|
|
|
|
Name : |
Ms. Saloni Rajen
Javeri |
|
Designation : |
Director |
|
Address: |
1002, Jayant Towers,
Tardeo Road, Tardeo, Mumbai - 400034 |
|
Date of Birth/Age : |
22 years |
|
|
|
|
Name : |
Ms. Suhagi Rajen
Javeri |
|
Designation : |
Director |
|
Address: |
1002, Jayant
Towers, Tardeo Road, Tardeo, Mumbai - 400034 |
|
Date of Birth/Age : |
25 years |
|
Name : |
Mr. Vinod B.Seth |
|
Designation : |
Partner |
|
Age : |
78 Years |
|
Qualification : |
B.Sc. Chemistry |
|
Experience : |
54 Years |
|
Previous Employment: |
Self Employed |
MAJOR SHAREHOLDERS
|
Names of
Shareholders |
No. of Shares |
Percentage of Holding |
|
Mrs Uma
Rajan Javeri |
40000 |
66.666 |
|
Ms Suhagi
Javeri |
10000 |
16.66 |
|
Ms Saloni
Javeri |
10000 |
16.66 |
|
Total |
60000 |
100.00 |
|
Line of Business : |
The concern act as
indenting house engaged in marketing of pharmaceutical raw materials from
foreign manufacturers to multinational/ Indian Pharma/ Chemical factories and
is also engaged in contract research. |
|
|
|
|
Products: |
Fudrajit – Roehm –
Gmbh, Vivapur – Jrs, Triethyl Citrate – Vertellus- USA, Colors – Sensient
Colors UK |
|
|
|
|
Agencies Held: |
|
|
Imports from : |
Germany, USA, U.K.,
Europe, China and Japan |
|
|
|
|
Terms : |
|
|
Purchasing
: |
D/A or D/P, Credit
: 90 days |
|
Suppliers : |
|
|
|
|
|
Customers : |
Manufacturer and
Actual Users |
|
|
|
|
No. of Employees : |
43 |
|
|
|
|
Bankers : |
Grindlays Bank, 90,
M.G.Road, Fort, Mumbai-400 001, India |
|
|
|
|
Facilities
: |
- |
|
|
|
|
Banking
Relations : |
- |
Authorised Capital
:
|
No. of Shares |
Type |
Value |
Amount |
|
50000 |
Equity Shares |
Rs.
10/- each |
Rs.
0.500 million |
Issued, Subscribed & Paid-up
Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
60000 |
Equity Shares |
Rs.
10/- each |
Rs.
0.600 million |
FINANCIAL DATA
[all
figures are in Rupees Millions]
|
Particulars |
31.03.2005 |
|
Sales Turnover |
50.000 |
History
Subject
is incorporated in the year 1951 at Mumbai, Maharashtra.
Now it become change
its name and style under S. Zhaveri Pharmakem Private Limited, w.e.f 6th June, 2005, having New
Company Registration Number U51397MH2005PTC153790.
The concern is in
trade terms with:
Local:
Foreign:
Website
details attached herewith-
Profile
The
company is not just another corporate success story, it is the reflection of
the determination of the post independence generation of businessmen to succeed
against odds. It is the saga of a great visionary, Vinod B Seth, Chemistry
graduate of the Mumbai Royal Institute of Science.
The company started introducing to India pharmaceutical
& chemical industry reputed manufacturers from Germany, Italy, Japan, USA
and other countries. This was an important service and contribution to Indian
importers and industry since they were able to import from reputed markets from
other countries at more competitive price. Since then the company has never
looked back and has been growing continuously. It has maintained strong customer
relations and enjoys high reputation in the pharmaceutical and chemical
industry for Service, Integrity and Performance.
Export of Bulk
Drugs/Active Pharmaceutical Ingrediants produced by reputed Indian produer to
world wide.
Import of drug-intermediates / Fine chemicals / Excipients for Indian
formulation industries.
Contract Research Organization : Develop pharmaceutical dossier in Solid dosage
form for Indian and as well as international companies.
Activity:
- Contract Research
- Licensing & Business Development
- Sales & Distribution
Product
/ Technology type(s) covered:
- API / chemicals
- Generics
Therapeutic targets:
- AIDS
- Asthma
- Cancer
- Cardiovascular
- Central nervous system
- Cough / Cold
- Diabetes
- Gastrointestinal
- Infectious Diseases
- Mental Health
- Oncology
- Pain
- Respiratory Medicine
Trade References
Mr Hiren Desai, Tel. No.:
91-22-28230202
Mr
DineshHegoe
Mr
Jitendra Jadhav, Tel. No.: 91-22-26534444
CMT REPORT [Corruption,
Money laundering & Terrorism]
The Public Notice
information has been collected from various sources including but not limited
to: The Courts, India Prisons Service, Interpol, etc.
1] INFORMATION ON DESIGNATED PARTY
No records exist designating subject or
any of its beneficial owners, controlling shareholders or senior officers as
terrorist or terrorist organization or whom notice had been received that all
financial transactions involving their assets have been blocked or convicted,
found guilty or against whom a judgement or order had been entered in a
proceedings for violating money-laundering, anti-corruption or bribery or international
economic or anti-terrorism sanction laws or whose assets were seized, blocked,
frozen or ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court Declaration :
No
records exist to suggest that subject is or was the subject of any formal or
informal allegations, prosecutions or other official proceeding for making any
prohibited payments or other improper payments to government officials for
engaging in prohibited transactions or with designated parties.
3] Asset Declaration :
No records exist to suggest that the
property or assets of the subject are derived from criminal conduct or a
prohibited transaction.
4] Record on Financial Crime :
Charges or conviction registered
against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or investigation registered
against subject: None
6] Records on Int’l Anti-Money
Laundering Laws/Standards :
Charges or investigation registered
against subject: None
7] Criminal Records
No available information exist that suggest that subject or
any of its principals have been formally charged or convicted by a competent
governmental authority for any financial crime or under any formal
investigation by a competent government authority for any violation of
anti-corruption laws or international anti-money laundering laws or standard.
8] Affiliation with Government :
No record exists to suggest that any director or indirect
owners, controlling shareholders, director, officer or employee of the company
is a government official or a family member or close business associate of a
Government official.
9] Compensation Package :
Our market survey revealed that the amount of compensation
sought by the subject is fair and reasonable and comparable to compensation
paid to others for similar services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE
GOVERNANCE
MIRA INFORM as part of
its Due Diligence do provide comments on Corporate Governance to identify
management and governance. These factors often have been predictive and in some
cases have created vulnerabilities to credit deterioration.
Our Governance
Assessment focuses principally on the interactions between a company’s
management, its Board of Directors, Shareholders and other financial
stakeholders.
CONTRAVENTION
Subject is not known
to have contravened any existing local laws, regulations or policies that
prohibit, restrict or otherwise affect the terms and conditions that could be
included in the agreement with the subject.
FOREIGN
EXCHANGE RATES
|
Currency |
Unit
|
Indian
Rupees |
|
US Dollar |
1 |
Rs.44.08 |
|
UK Pound |
1 |
Rs.78.04 |
|
Euro |
1 |
Rs.53.04 |
|
SCORE
FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
5 |
|
PAID-UP CAPITAL |
1~10 |
5 |
|
OPERATING SCALE |
1~10 |
5 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
5 |
|
--PROFITABILIRY |
1~10 |
5 |
|
--LIQUIDITY |
1~10 |
5 |
|
--LEVERAGE |
1~10 |
5 |
|
--RESERVES |
1~10 |
5 |
|
--CREDIT LINES |
1~10 |
5 |
|
--MARGINS |
-5~5 |
- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
NO |
|
--AFFILIATION |
YES/NO |
NO |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
TOTAL |
|
45 |
This score serves as a reference to
assess SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors and their relative weights (as
indicated through %) are as follows:
Financial condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history (10%) Market
trend (10%) Operational
size (10%)
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound
financial base with the strongest capability for timely payment of interest
and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working
capital. No caution needed for credit transaction. It has above average (strong)
capability for payment of interest and principal sums |
Large |
|
56-70 |
A |
Financial & operational base
are regarded healthy. General unfavourable factors will not cause fatal effect.
Satisfactory capability for payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered
normal. Capable to meet normal commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors
carry similar weight in credit consideration. Capability to overcome
financial difficulties seems comparatively below average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent.
Repayment of interest and principal sums in default or expected to be in
default upon maturity |
Limited with full security |
|
<10 |
C |
Absolute credit risk exists.
Caution needed to be exercised |
Credit not recommended |